Absorption of CH330331, a novel 4-anilinoquinazoline inhibitor of epidermal growth factor receptor tyrosine kinase

Comparative studies using in vitro, in situ and in vivo models

Haiyan Sun, Huichang Bi, Min Huang, Dong Liu, Zhenyu Qin

Research output: Contribution to journalArticle

Abstract

CH330331 is a prototype of a new class of synthetic small molecule tyrosine kinase inhibitors (TKIs). In vitro Caco-2 cell monolayers, the in situ single-pass rat intestinal perfusion (SPIP) technique with mesenteric vein cannulated and an in vivo animal model were employed to investigate its permeability and transepithelial transport mechanisms. The Caco-2 model showed that the transport of CH330331 across the monolayers from the apical (AP) to basolateral (BL) side was 6- to 10-fold higher than that from the BL to AP side. The apparent permeability coefficient (Papp) values of CH330331 at 5-20 μg/ml from the AP to BL and from BL to AP side were 5.30-2.21 × 10-6 cm/s, with a decrease in Papp values from the AP to BL side at increased CH330331 concentrations. In the perfused rat intestinal model, a concentration dependent change in permeability was detected where Pblood at 5 μg/ml (1.66 ± 0.69 × 10-6 cm/s) and 10 μg/ml (1.80 ± 0.45 × 10-6 cm/s) was significantly different from Pblood at 20 μg/ml (0.98 ± 0.31 × 10-6 cm/s, p<0.05). Some inhibitors could also change the transepithelial transport of CH330331. Moreover, the in vivo study showed that the oral bioavailability of CH330331 was 82.7% in the rat. All the results confirmed that the transepithelial transport of CH330331 was rapid and saturable, which might involve an active mechanism. The oral bioavailability of CH330331 was relatively high in vivo.

Original languageEnglish (US)
Pages (from-to)486-494
Number of pages9
JournalBiopharmaceutics and Drug Disposition
Volume31
Issue number8-9
DOIs
StatePublished - Nov 2010
Externally publishedYes

Fingerprint

Epidermal Growth Factor Receptor
Protein-Tyrosine Kinases
Permeability
Biological Availability
Mesenteric Veins
Caco-2 Cells
Animal Models
Perfusion
In Vitro Techniques

Keywords

  • bioavailability
  • Caco-2
  • CH330331
  • single-pass rat intestinal perfusion model

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmaceutical Science
  • Pharmacology

Cite this

Absorption of CH330331, a novel 4-anilinoquinazoline inhibitor of epidermal growth factor receptor tyrosine kinase : Comparative studies using in vitro, in situ and in vivo models. / Sun, Haiyan; Bi, Huichang; Huang, Min; Liu, Dong; Qin, Zhenyu.

In: Biopharmaceutics and Drug Disposition, Vol. 31, No. 8-9, 11.2010, p. 486-494.

Research output: Contribution to journalArticle

@article{e0aaba52ad1d4fbbb29f6c264db751ed,
title = "Absorption of CH330331, a novel 4-anilinoquinazoline inhibitor of epidermal growth factor receptor tyrosine kinase: Comparative studies using in vitro, in situ and in vivo models",
abstract = "CH330331 is a prototype of a new class of synthetic small molecule tyrosine kinase inhibitors (TKIs). In vitro Caco-2 cell monolayers, the in situ single-pass rat intestinal perfusion (SPIP) technique with mesenteric vein cannulated and an in vivo animal model were employed to investigate its permeability and transepithelial transport mechanisms. The Caco-2 model showed that the transport of CH330331 across the monolayers from the apical (AP) to basolateral (BL) side was 6- to 10-fold higher than that from the BL to AP side. The apparent permeability coefficient (Papp) values of CH330331 at 5-20 μg/ml from the AP to BL and from BL to AP side were 5.30-2.21 × 10-6 cm/s, with a decrease in Papp values from the AP to BL side at increased CH330331 concentrations. In the perfused rat intestinal model, a concentration dependent change in permeability was detected where Pblood at 5 μg/ml (1.66 ± 0.69 × 10-6 cm/s) and 10 μg/ml (1.80 ± 0.45 × 10-6 cm/s) was significantly different from Pblood at 20 μg/ml (0.98 ± 0.31 × 10-6 cm/s, p<0.05). Some inhibitors could also change the transepithelial transport of CH330331. Moreover, the in vivo study showed that the oral bioavailability of CH330331 was 82.7{\%} in the rat. All the results confirmed that the transepithelial transport of CH330331 was rapid and saturable, which might involve an active mechanism. The oral bioavailability of CH330331 was relatively high in vivo.",
keywords = "bioavailability, Caco-2, CH330331, single-pass rat intestinal perfusion model",
author = "Haiyan Sun and Huichang Bi and Min Huang and Dong Liu and Zhenyu Qin",
year = "2010",
month = "11",
doi = "10.1002/bdd.729",
language = "English (US)",
volume = "31",
pages = "486--494",
journal = "Biopharmaceutics and Drug Disposition",
issn = "0142-2782",
publisher = "John Wiley and Sons Ltd",
number = "8-9",

}

TY - JOUR

T1 - Absorption of CH330331, a novel 4-anilinoquinazoline inhibitor of epidermal growth factor receptor tyrosine kinase

T2 - Comparative studies using in vitro, in situ and in vivo models

AU - Sun, Haiyan

AU - Bi, Huichang

AU - Huang, Min

AU - Liu, Dong

AU - Qin, Zhenyu

PY - 2010/11

Y1 - 2010/11

N2 - CH330331 is a prototype of a new class of synthetic small molecule tyrosine kinase inhibitors (TKIs). In vitro Caco-2 cell monolayers, the in situ single-pass rat intestinal perfusion (SPIP) technique with mesenteric vein cannulated and an in vivo animal model were employed to investigate its permeability and transepithelial transport mechanisms. The Caco-2 model showed that the transport of CH330331 across the monolayers from the apical (AP) to basolateral (BL) side was 6- to 10-fold higher than that from the BL to AP side. The apparent permeability coefficient (Papp) values of CH330331 at 5-20 μg/ml from the AP to BL and from BL to AP side were 5.30-2.21 × 10-6 cm/s, with a decrease in Papp values from the AP to BL side at increased CH330331 concentrations. In the perfused rat intestinal model, a concentration dependent change in permeability was detected where Pblood at 5 μg/ml (1.66 ± 0.69 × 10-6 cm/s) and 10 μg/ml (1.80 ± 0.45 × 10-6 cm/s) was significantly different from Pblood at 20 μg/ml (0.98 ± 0.31 × 10-6 cm/s, p<0.05). Some inhibitors could also change the transepithelial transport of CH330331. Moreover, the in vivo study showed that the oral bioavailability of CH330331 was 82.7% in the rat. All the results confirmed that the transepithelial transport of CH330331 was rapid and saturable, which might involve an active mechanism. The oral bioavailability of CH330331 was relatively high in vivo.

AB - CH330331 is a prototype of a new class of synthetic small molecule tyrosine kinase inhibitors (TKIs). In vitro Caco-2 cell monolayers, the in situ single-pass rat intestinal perfusion (SPIP) technique with mesenteric vein cannulated and an in vivo animal model were employed to investigate its permeability and transepithelial transport mechanisms. The Caco-2 model showed that the transport of CH330331 across the monolayers from the apical (AP) to basolateral (BL) side was 6- to 10-fold higher than that from the BL to AP side. The apparent permeability coefficient (Papp) values of CH330331 at 5-20 μg/ml from the AP to BL and from BL to AP side were 5.30-2.21 × 10-6 cm/s, with a decrease in Papp values from the AP to BL side at increased CH330331 concentrations. In the perfused rat intestinal model, a concentration dependent change in permeability was detected where Pblood at 5 μg/ml (1.66 ± 0.69 × 10-6 cm/s) and 10 μg/ml (1.80 ± 0.45 × 10-6 cm/s) was significantly different from Pblood at 20 μg/ml (0.98 ± 0.31 × 10-6 cm/s, p<0.05). Some inhibitors could also change the transepithelial transport of CH330331. Moreover, the in vivo study showed that the oral bioavailability of CH330331 was 82.7% in the rat. All the results confirmed that the transepithelial transport of CH330331 was rapid and saturable, which might involve an active mechanism. The oral bioavailability of CH330331 was relatively high in vivo.

KW - bioavailability

KW - Caco-2

KW - CH330331

KW - single-pass rat intestinal perfusion model

UR - http://www.scopus.com/inward/record.url?scp=78649670848&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78649670848&partnerID=8YFLogxK

U2 - 10.1002/bdd.729

DO - 10.1002/bdd.729

M3 - Article

VL - 31

SP - 486

EP - 494

JO - Biopharmaceutics and Drug Disposition

JF - Biopharmaceutics and Drug Disposition

SN - 0142-2782

IS - 8-9

ER -